This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Arnold, A. E. Articles by Verstraete, M. Search for Related Content PubMed PubMed Citation Articles by Arnold, A. E. Articles by Verstraete, M. Pubmed/NCBI databases Substance via MeSH Medline Plus Health Information Angioplasty Heart Attack

Circulation, Vol 86, 111-120, Copyright © 1992 by American Heart Association

ARTICLES

Recombinant tissue-type plasminogen activator and immediate angioplasty in acute myocardial infarction. One-year follow-up. The European Cooperative Study Group [published errata appear in Circulation 1993 May;87(5):1775 and 1993 Jun;87(6):2070]

AE Arnold, ML Simoons, F Van de Werf, DP de Bono, J Lubsen, JG Tijssen, PW Serruys and M Verstraete
Center for Clinical Decision Analysis, Erasmus University, Rotterdam, The Netherlands.

BACKGROUND. The European Cooperative Study Group conducted two randomized trials in patients with suspected myocardial infarction to assess the effect of 100 mg single-chain recombinant tissue-type plasminogen activator (rt-PA, alteplase) on enzymatic infarct size, left ventricular function, morbidity and mortality relative to placebo (alteplase/placebo trial) and to assess the effect of immediate percutaneous transluminal coronary angioplasty (PTCA) in addition to alteplase (alteplase/PTCA trial). One-year follow-up results are reported. METHODS AND RESULTS. In the alteplase/placebo trial, 721 patients with chest pain of less than 5 hours and extensive ST-segment elevation were allocated at random to 100 mg alteplase or placebo (double-blind) over 3 hours. In the alteplase/PTCA trial, 367 similar patients received alteplase and subsequently were allocated at random to immediate coronary angiography and angioplasty of the infarct- related vessel or control. All patients received aspirin and intravenous heparin. In the alteplase/placebo trial, mortality during the first year was reduced by 36% with alteplase (from 9.3% to 5.6%; difference, -3.7%; 95% confidence interval, -7.5% to 0.2%). Revascularization was performed more frequently after alteplase, and more patients in the alteplase group were in New York Heart Association functional class I or II. Reinfarction tended to occur more frequently after alteplase than after placebo. In the alteplase/PTCA trial, reinfarction was less common after immediate PTCA, and revascularization procedures were less frequent. However, this benefit was offset by a high rate of immediate reocclusion and early recurrent ischemia and by higher mortality at 1 year (9.3% versus 5.4%; difference, 3.9%; 95% confidence interval, -1.5% to 9.2%) in the invasive group. In a multivariate analysis of 1,043 hospital survivors, mortality after discharge was related to coronary anatomy, left ventricular function, age, and previous infarction but not to initial treatment allocation. Reinfarction after hospital discharge tended to be more common after alteplase and related to coronary anatomy. CONCLUSIONS. Benefit from treatment with alteplase, heparin, and aspirin is not diminished at 1 year. Routine immediate PTCA does not confer additional benefit. Prognosis after hospital discharge mainly is determined by coronary anatomy and residual left ventricular function and is unrelated to initial treatment assignment.

This article has been cited by other articles:

				M. C. Moon, J. Pablo Morales, and R. K. Greenberg Complicated Acute Type B Dissection and Endovascular Repair: Indications and Pitfalls Perspectives in Vascular Surgery and Endovascular Therapy, June 1, 2007; 19(2): 146 - 159. [Abstract] [PDF]

				W. B. Borden and D. P. Faxon Facilitated Percutaneous Coronary Intervention J. Am. Coll. Cardiol., September 19, 2006; 48(6): 1120 - 1128. [Abstract] [Full Text] [PDF]

				W. J. Cantor, F. Brunet, C. P. Ziegler, A. Kiss, and L. J. Morrison Immediate angioplasty after thrombolysis: a systematic review Can. Med. Assoc. J., December 6, 2005; 173(12): 1473 - 1481. [Abstract] [Full Text] [PDF]

				E. M. Antman and F. Van de Werf Pharmacoinvasive Therapy: The Future of Treatment for ST-Elevation Myocardial Infarction Circulation, June 1, 2004; 109(21): 2480 - 2486. [Full Text] [PDF]

				P. J. Scanlon, D. P. Faxon, A.-M. Audet, B. Carabello, G. J. Dehmer, K. A. Eagle, R. D. Legako, D. F. Leon, J. A. Murray, S. E. Nissen, et al. ACC/AHA guidelines for coronary angiography: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Coronary Angiography) developed in collaboration with the Society for Cardiac Angiography and Interventions J. Am. Coll. Cardiol., May 1, 1999; 33(6): 1756 - 1824. [Full Text] [PDF]

				T. Lenderink, M. L. Simoons, G.-A. Van Es, F. Van de Werf, M. Verstraete, and A. E.R. Arnold Benefit of Thrombolytic Therapy Is Sustained Throughout Five Years and Is Related to TIMI Perfusion Grade 3 But Not Grade 2 Flow at Discharge Circulation, September 1, 1995; 92(5): 1110 - 1116. [Abstract] [Full Text]

				K. B. Michels and S. Yusuf Does PTCA in Acute Myocardial Infarction Affect Mortality and Reinfarction Rates? : A Quantitative Overview (Meta-Analysis) of the Randomized Clinical Trials Circulation, January 15, 1995; 91(2): 476 - 485. [Abstract] [Full Text]

				C. Landau, R. A. Lange, and L. D. Hillis Percutaneous Transluminal Coronary Angioplasty N. Engl. J. Med., April 7, 1994; 330(14): 981 - 993. [Full Text]